BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 16475213)

  • 1. A Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
    Kim ST; Park JO; Lee J; Lee KT; Lee JK; Choi SH; Heo JS; Park YS; Kang WK; Park K
    Cancer; 2006 Mar; 106(6):1339-46. PubMed ID: 16475213
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study of capecitabine and cisplatin in previously untreated advanced biliary tract cancer.
    Hong YS; Lee J; Lee SC; Hwang IG; Choi SH; Heo JS; Park JO; Park YS; Lim HY; Kang WK
    Cancer Chemother Pharmacol; 2007 Aug; 60(3):321-8. PubMed ID: 17143602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
    Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
    Lee J; Kim TY; Lee MA; Ahn MJ; Kim HK; Lim HY; Lee NS; Park BJ; Kim JS;
    Cancer Chemother Pharmacol; 2008 Jan; 61(1):47-52. PubMed ID: 17364190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gemcitabine and irinotecan in locally advanced or metastatic biliary cancer: preliminary report.
    Bhargava P; Jani CR; Savarese DM; O'Donnell JL; Stuart KE; Rocha Lima CM
    Oncology (Williston Park); 2003 Sep; 17(9 Suppl 8):23-6. PubMed ID: 14569844
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of gemcitabine and cisplatin in advanced biliary tract cancer.
    Park BK; Kim YJ; Park JY; Bang S; Park SW; Chung JB; Kim KS; Choi JS; Lee WJ; Song SY
    J Gastroenterol Hepatol; 2006 Jun; 21(6):999-1003. PubMed ID: 16724985
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma.
    Philip PA; Zalupski MM; Vaitkevicius VK; Arlauskas P; Chaplen R; Heilbrun LK; Adsay V; Weaver D; Shields AF
    Cancer; 2001 Aug; 92(3):569-77. PubMed ID: 11505401
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with gemcitabine and oxaliplatin in patients with advanced biliary tract cancer: a single-institution experience.
    Manzione L; Romano R; Germano D
    Oncology; 2007; 73(5-6):311-5. PubMed ID: 18493158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial.
    Alberts SR; Al-Khatib H; Mahoney MR; Burgart L; Cera PJ; Flynn PJ; Finch TR; Levitt R; Windschitl HE; Knost JA; Tschetter LK
    Cancer; 2005 Jan; 103(1):111-8. PubMed ID: 15558814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
    Thongprasert S; Napapan S; Charoentum C; Moonprakan S
    Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.
    Riechelmann RP; Townsley CA; Chin SN; Pond GR; Knox JJ
    Cancer; 2007 Sep; 110(6):1307-12. PubMed ID: 17628484
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.
    Rimini M; Masi G; Lonardi S; Nichetti F; Pressiani T; Lavacchi D; Jessica L; Giordano G; Scartozzi M; Tamburini E; Pastorino A; Rapposelli IG; Daniele B; Martinelli E; Garajova I; Aprile G; Schirripa M; Formica V; Salani F; Winchler C; Bergamo F; Balsano R; Gusmaroli E; Lorenzo A; Landriscina M; Pretta A; Toma I; Pirrone C; Diana A; Leone F; Brunetti O; Brandi G; Garattini SK; Satolli MA; Rossari F; Fornaro L; Niger M; Zanuso V; De Rosa A; Ratti F; Aldrighetti L; De Braud F; Foti S; Rizzato MD; Vivaldi C; Stefano C; Rimassa L; Antonuzzo L; Casadei-Gardini A
    Target Oncol; 2024 May; 19(3):359-370. PubMed ID: 38691295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gemcitabine combined with oxaliplatin (GEMOX) in advanced biliary tract adenocarcinoma: a GERCOR study.
    André T; Tournigand C; Rosmorduc O; Provent S; Maindrault-Goebel F; Avenin D; Selle F; Paye F; Hannoun L; Houry S; Gayet B; Lotz JP; de Gramont A; Louvet C;
    Ann Oncol; 2004 Sep; 15(9):1339-43. PubMed ID: 15319238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II trial of S-1 and cisplatin in patients with metastatic or relapsed biliary tract cancer.
    Kim YJ; Im SA; Kim HG; Oh SY; Lee KW; Choi IS; Oh DY; Lee SH; Kim JH; Kim DW; Kim TY; Kim SW; Heo DS; Yoon YB; Bang YJ
    Ann Oncol; 2008 Jan; 19(1):99-103. PubMed ID: 17846018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group.
    Bamias A; Moulopoulos LA; Koutras A; Aravantinos G; Fountzilas G; Pectasides D; Kastritis E; Gika D; Skarlos D; Linardou H; Kalofonos HP; Dimopoulos MA
    Cancer; 2006 Jan; 106(2):297-303. PubMed ID: 16342065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of gemcitabine/doxorubicin/paclitaxel administered every other week in patients with metastatic breast cancer.
    Sánchez-Rovira P; Jaén A; González E; Porras I; Dueñas MR; Medina B; Mohedano N; Fernández M; Martos M; Lozano A
    Clin Breast Cancer; 2000 Oct; 1(3):226-32. PubMed ID: 11899647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel, cisplatin, and gemcitabine combination chemotherapy within a multidisciplinary therapeutic approach in metastatic nonsmall cell lung carcinoma.
    Rodriguez J; Cortes J; Calvo E; Azinovic I; Fernandez-Hildago O; Martinez-Monge R; Garzon C; de Irala J; Martinez-Aguillo M; Ramon Y Cajal T; Brugarolas A
    Cancer; 2000 Dec; 89(12):2622-9. PubMed ID: 11135224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fixed-dose-rate gemcitabine: a viable first-line treatment option for advanced pancreatic and biliary tract cancer.
    Milella M; Gelibter AJ; Pino MS; Bossone G; Marolla P; Sperduti I; Cognetti F
    Oncologist; 2010; 15(2):e1-4. PubMed ID: 20189980
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase II trial of the use of gemcitabine and 5-fluorouracil in the treatment of advanced pancreatic and biliary tract cancer.
    Murad AM; Guimarães RC; Aragão BC; Rodrigues VH; Scalabrini-Neto AO; Padua CA; Moore FC
    Am J Clin Oncol; 2003 Apr; 26(2):151-4. PubMed ID: 12714886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced/metastatic biliary tract carcinoma.
    Cho JY; Paik YH; Chang YS; Lee SJ; Lee DK; Song SY; Chung JB; Park MS; Yu JS; Yoon DS
    Cancer; 2005 Dec; 104(12):2753-8. PubMed ID: 16294346
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.